{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:58:38Z","timestamp":1779119918397,"version":"3.51.4"},"reference-count":24,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,10,10]]},"DOI":"10.1253\/circrep.cr-25-0079","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:07:24Z","timestamp":1755036444000},"page":"852-860","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Outcomes of Patients With Non-Valvular Atrial Fibrillation on Anticoagulants Ineligible for Phase III Trials of Direct Oral Anticoagulants\u3000\u2015 A Retrospective Cohort Study \u2015"],"prefix":"10.1253","volume":"7","author":[{"given":"Mayumi","family":"Higa","sequence":"first","affiliation":[{"name":"Department of Clinical Research and Management, University of the Ryukyus Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Hyogo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Kagawa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Management, University of the Ryukyus Graduate School of Medicine"},{"name":"Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus Graduate School of Medicine"},{"name":"Department of Health Data Science, Yokohama City University Graduate School of Data Science"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2009; 361: 1139\u20131151.","DOI":"10.1056\/NEJMoa0905561"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>N Engl J Med<\/i> 2011; 365: 883\u2013891.","DOI":"10.1056\/NEJMoa1009638"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. <i>Circ J<\/i> 2012; 76: 2104\u20132111.","DOI":"10.1253\/circj.CJ-12-0454"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2011; 365: 981\u2013992.","DOI":"10.1056\/NEJMoa1107039"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2013; 369: 2093\u20132104.","DOI":"10.1056\/NEJMoa1310907"},{"key":"6","unstructured":"6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Enhancing the diversity of clinical trial populations---Eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020. https:\/\/digirepo.nlm.nih.gov\/master\/borndig\/9918249008406676\/9918249008406676.pdf (accessed February 8, 2022)."},{"key":"7","unstructured":"7. ICH Steering Committee. ICH harmonised tripartite guideline: General considerations for clinical trials. 1997. https:\/\/www.pmda.go.jp\/files\/000156703.pdf (accessed February 8, 2022)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: A cross-sectional analysis using the General Practice Research Database. <i>BMJ Open<\/i> 2012; 2: e001768.","DOI":"10.1136\/bmjopen-2012-001768"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yoon CH, Park YK, Kim SJ, Lee MJ, Ryoo S, Kim GM, et al. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: Comparison between patients with versus without stroke. <i>Stroke<\/i> 2014; 45: 2983\u20132988.","DOI":"10.1161\/STROKEAHA.114.005599"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. H\u00e4gg L, Johansson C, Jansson JH, Johansson L. External validity of the Aristotle trial in real-life atrial fibrillation patients. <i>Cardiovasc Ther<\/i> 2014; 32: 214\u2013218.","DOI":"10.1111\/1755-5922.12087"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Desmaele S, Steurbaut S, Cornu P, Brouns R, Dupont AG. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: How representative are they for real-life patients? <i>Eur J Clin Pharmacol<\/i> 2016; 72: 1125\u20131134.","DOI":"10.1007\/s00228-016-2078-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fanning L, Ilom\u00e4ki J, Bell JS, D\u0101rzi\u0146\u0161 P. The representativeness of direct oral anticoagulant clinical trials to hospitalised patients with atrial fibrillation. <i>Eur J Clin Pharmacol<\/i> 2017; 73: 1427\u20131436.","DOI":"10.1007\/s00228-017-2297-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hughey AB, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, et al. Warfarin for prevention of thromboembolism in atrial fibrillation: Comparison of patient characteristics and outcomes of the \u2018Real-World\u2019 Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>J Thromb Thrombolysis<\/i> 2018; 46: 316\u2013324.","DOI":"10.1007\/s11239-018-1698-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. <i>Pharmacoepidemiol Drug Saf<\/i> 2021; 30: 1321\u20131331.","DOI":"10.1002\/pds.5228"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of atrial fibrillation. <i>JAMA<\/i> 2001; 285: 2864\u20132870.","DOI":"10.1001\/jama.285.22.2864"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. <i>Chest<\/i> 2010; 138: 1093\u20131100.","DOI":"10.1378\/chest.10-0134"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>J Thromb Haemost<\/i> 2005; 3: 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. <i>Circulation<\/i> 1987; 76: 142\u2013154.","DOI":"10.1161\/01.CIR.76.1.142"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tsuda T, Hayashi K, Kato T, Kusayama T, Nakagawa Y, Nomura A, et al. Effects of longitudinal changes in anemia status on clinical outcomes in patients with non-valvular atrial fibrillation: Analysis from the Hokuriku-Plus AF Registry. <i>Circ J<\/i> 2025; 89: 164\u2013173.","DOI":"10.1253\/circj.CJ-24-0132"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hara T, Sata M. Current real-world status of oral anticoagulant management in Japanese patients. <i>Circ J<\/i> 2025; 89: 150\u2013152.","DOI":"10.1253\/circj.CJ-24-0827"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Masunaga N, Ishii M, Oka K, Okamoto K, Yoshida Y, Minami K, et al. 10-Year trends of antithrombotic therapy status and clinical outcomes in patients with atrial fibrillation and renal dysfunction: The Fushimi AF Registry. <i>Circ J<\/i> 2025; 89: 174\u2013183.","DOI":"10.1253\/circj.CJ-24-0614"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takagi Y, Ueda S. Factors related to the choice of warfarin for treating newly diagnosed nonvalvular atrial fibrillation are associated with safety outcomes during anticoagulation: A new-user, active-comparator, retrospective cohort study. <i>J Arrhythm<\/i> 2024; 40: 1408\u20131424.","DOI":"10.1002\/joa3.13160"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bejjani A, Khairani CD, Assi A, Piazza G, Sadeghipour P, Talasaz AH, et al. When direct oral anticoagulants should not be standard treatment: JACC State-of-the-Art Review. <i>J Am Coll Cardiol<\/i> 2024; 83: 444\u2013465.","DOI":"10.1016\/j.jacc.2023.10.038"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. G\u00f3mez-Outes A, Lagunar-Ru\u00edz J, Terleira-Fern\u00e1ndez AI, Calvo-Rojas G, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E. Causes of death in anticoagulated patients with atrial fibrillation. <i>J Am Coll Cardiol<\/i> 2016; 68: 2508\u20132521.","DOI":"10.1016\/j.jacc.2016.09.944"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/10\/7_CR-25-0079\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:06:13Z","timestamp":1760155573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/10\/7_CR-25-0079\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0079","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"CR-25-0079"}}